{"entity":{"id":"spatial-omics-guided-therapy","kind":"technology","name":"Spatial-omics-guided treatment selection","aka":[],"tldr":"Choosing treatment from a map of where each cell type sits in the tumour, not just from a list of its mutations.","summary":"Spatial transcriptomics and multiplex imaging show that immune exclusion, stromal barriers and clonal geography predict response in ways bulk sequencing cannot; tertiary lymphoid structures, for example, predict immunotherapy benefit across tumour types. Turning these maps into a clinical assay requires standardisation, lower cost and prospective validation. Today they are correlative science inside trials, not decision tools.","status":"emerging","asOf":"2026-09-08","links":[{"label":"ClinicalTrials.gov: spatial transcriptomics cancer","url":"https://clinicaltrials.gov/search?term=spatial%20transcriptomics%20cancer"}],"tags":["frontier","promising"],"related":[],"cancers":[],"sections":["diagnostics","ai-computation"],"technologies":["single-cell-spatial","digital-pathology-ai","pathology-foundation-model","proteomics"],"targets":[],"drugs":[],"companies":["10x-genomics","owkin","bostongene"],"institutions":[],"pathways":[],"terms":["cold-vs-hot","tils"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Spatially resolved RNA or protein profiling quantifies the architecture of the tumour microenvironment; machine learning turns that architecture into a predictive score.","strengths":["Captures exclusion and heterogeneity that bulk assays average away","Uses the same tissue block as routine pathology","Predictive features already identified"],"limitations":["Cost and turnaround far from clinical","No standardised platform or scoring","Prospective validation missing"]},"route":"/technologies/spatial-omics-guided-therapy/","neighbours":{"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"digital-pathology-ai","kind":"technology","name":"Digital pathology & AI","route":"/technologies/digital-pathology-ai/"},{"id":"pathology-foundation-model","kind":"technology","name":"Pathology & radiology foundation models","route":"/technologies/pathology-foundation-model/"},{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/"},{"id":"single-cell-spatial","kind":"technology","name":"Single-cell & spatial profiling","route":"/technologies/single-cell-spatial/"}],"company":[{"id":"10x-genomics","kind":"company","name":"10x Genomics","route":"/companies/10x-genomics/"},{"id":"bostongene","kind":"company","name":"BostonGene","route":"/companies/bostongene/"},{"id":"owkin","kind":"company","name":"Owkin","route":"/companies/owkin/"}],"term":[{"id":"cold-vs-hot","kind":"term","name":"Hot vs cold tumours","route":"/terms/cold-vs-hot/"},{"id":"tils","kind":"term","name":"Tumour-infiltrating lymphocytes (TILs)","route":"/terms/tils/"}],"roadmap":[{"id":"diagnostics-roadmap","kind":"roadmap","name":"Diagnostics roadmap: stains → gene panels → blood tests that decide treatment","route":"/roadmaps/diagnostics-roadmap/"},{"id":"cure-paths","kind":"roadmap","name":"Paths to cures: interception, eradication, control","route":"/roadmaps/cure-paths/"},{"id":"frontier-2035","kind":"roadmap","name":"Radical oncology: what could change the war by 2035","route":"/roadmaps/frontier-2035/"}]}}